Christopher Szyarto, DO
Hematology & Oncology · Flint, MINPI 1942243597
Payments from drug & device makers
Across 120 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$534
- Merck$200
- Johnson & Johnson$144
- Axsome Therapeutics, Inc.$119
- GSK$94
- Pfizer$90
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,26395%
- Education$1165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $534 |
| Merck | 5 | $200 |
| Johnson & Johnson(2 entities) | 3 | $144 |
| Axsome Therapeutics, Inc. | 1 | $119 |
| GSK | 5 | $94 |
| Pfizer | 6 | $90 |
| AstraZeneca(2 entities) | 5 | $90 |
| AbbVie | 3 | $88 |
| EMD Serono, Inc. | 3 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $85 |
| Genentech USA, Inc. | 5 | $80 |
| Gilead(2 entities) | 5 | $72 |
| Deciphera Pharmaceuticals Inc. | 4 | $69 |
| Sanofi | 3 | $68 |
| Astellas Pharma US Inc | 3 | $66 |
| Stemline Therapeutics Inc. | 3 | $64 |
| G1 Therapeutics, Inc. | 3 | $47 |
| Rigel Pharmaceuticals, Inc. | 3 | $45 |
| Bristol Myers Squibb | 2 | $39 |
| Seagen Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $29 |
| Coherus Oncology, Inc. | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Menarini Silicon Biosystems, Inc. | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Array Biopharma Inc | 1 | $16 |
| Amgen | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Emmaus Medical, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $14 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,510 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 58 | $1,475,243 |
| Lenalidomide | 71 | $1,139,773 |
| XtandiEnzalutamide | 55 | $733,982 |
| ImbruvicaIbrutinib | 31 | $519,363 |
| IbrancePalbociclib | 30 | $474,677 |
| BrukinsaZanubrutinib | 19 | $279,579 |
| TasignaNilotinib Hcl | 13 | $273,723 |
| TagrissoOsimertinib Mesylate | 15 | $267,605 |
| JakafiRuxolitinib Phosphate | 15 | $262,129 |
| CalquenceAcalabrutinib Maleate | 11 | $167,888 |
| VenclextaVenetoclax | 14 | $160,344 |
| Abiraterone Acetate | 14 | $84,598 |
| EliquisApixaban | 73 | $81,005 |
| NeulastaPegfilgrastim | 13 | $79,819 |
| Exemestane | 170 | $63,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $39 | $1,475,24358 claims |
| Astellas Pharma US IncXtandi | $66 | $733,98255 claims |
| PfizerIbrance, Eliquis | $90 | $555,682103 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $29 | $519,36331 claims |
| AstraZenecaTagrisso, Calquence | $90 | $435,49326 claims |
| NovartisTasigna | $534 | $273,72313 claims |
| Incyte CorporationJakafi | $21 | $262,12915 claims |
| AbbVieVenclexta | $88 | $160,34414 claims |
| AmgenNeulasta | $15 | $79,81913 claims |
| Johnson & JohnsonXarelto | $144 | $49,43758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Flint
- Madan AroraFlint$84K
- Paul AdamsFlint$76K
- Rizwan DanishFlint$49K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.